Table 2.
Within-group and between-group changes from baseline of anthropometric and laboratory measurements
| Variable | Change from baseline to 26 weeks | Mean (95% CI) change from baseline (liraglutide vs placebo) | p value | |
|---|---|---|---|---|
| Liraglutide (n = 23) | Placebo (n = 26) | |||
| Anthropometric measures | ||||
| Weight, kg | −4.3 ± 3.8 | 0.1 ± 2.5 | −4.5 (−6.4, −2.6) | <0.001 |
| BMI, kg/m2 | −1.5 ± 1.3 | 0.1 ± 0.8 | −1.5 (−2.2, −0.9) | <0.001 |
| Waist, cm | −1 ± 4 | 2 ± 4 | −3 (−5, −1) | 0.004 |
| Hip, cm | −2 ± 5 | 1 ± 2 | −3 (−5, −1) | 0.002 |
| Waist:hip ratio | 0.01 ± 0.04 | 0.01 ± 0.04 | 0.00 (−0.02, 0.03) | 0.69 |
| Laboratory measures | ||||
| Triacylglycerols, mmol/l | −0.5 ± 1.1 | −0.61.0 | 0.2 (−0.1, 0.6) | 0.18 |
| NEFA, mmol/l | −0.1 ± 0.2 | −0.1 ± 0.5 | −0.1 (−0.2, 0.1) | 0.39 |
| Total cholesterol, mmol/l | −0.7 ± 0.9 | −0.5 ± 0.6 | −0.22 (−0.59, 0.15) | 0.23 |
| HDL-c, mmol/l | −0.0 ± 0.1 | 0.1 ± 0.3 | −0.1 (−0.2, 0.1) | 0.22 |
| LDL-c, mmol/l | −0.4 ± 0.5 | −0.2 ± 0.5 | −0.17 (−0.44, 0.10) | 0.22 |
| HbA1c, mmol/mol | −11.6 ± 11.1 | −7.7 ± 9.4 | −2.9 (−8.1, 2.3) | 0.27 |
| HbA1c, % | −1.1 ± 1.0 | −0.7 ± 0.9 | −0.3 (−0.8, 0.2) | 0.27 |
| Adiponectin, mg/l | −0.5 ± 1.8 | −0.8 ± 2.0 | 0.2 (−0.9, 1.4) | 0.67 |
| AST, U/l | −6 ± 11 | −1 ± 22 | 2 (−3, 6) | 0.46 |
| ALT, U/l | 16 ± 12 | 14 ± 10 | 1 (−5, 7) | 0.78 |
| AP, U/l | 5 ± 11 | 6 ± 8 | −1 (−7, 5) | 0.76 |
| GGT, U/l | 1 ± 18 | −3 ± 11 | 3 (−6, 12) | 0.47 |
Data are presented as mean ± SD
AP, alkaline phosphatase; HDL-c, HDL-cholesterol; LDL-c, LDL-cholesterol